<DOC>
	<DOCNO>NCT01340235</DOCNO>
	<brief_summary>Dowling Meara type epidermolysis bullosa simplex ( EBS-DM ) rare genodermatosis due keratin 5 14 mutation , characterize skin fragility spontaneous post traumatic blister . Neonatal period infancy critical since autonomic dominant affection usually improve age . Cyclins seem efficient case EBS prohibit child young 8 year old . Erythromycin good alternative population due antibacterial anti-inflammatory potential . The aim study evaluation efficiency oral erythromycin decrease number cutaneous blister severe EBS-DM patient 6 month 8 year old 3 month treatment . Primary end point number patient decrease blister ' number least 20 % 3 month treatment oral erythromycin . It preliminary study 8 patient . Treatment oral erythromycin twice day 3 month . Follow patient 5 month . The duration study 1 year .</brief_summary>
	<brief_title>Treatment Dowling Maera Type Epidermolysis Bullosa Simplex Oral Erythromycin</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Simplex</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<criteria>Severe Dowling Meara EBS patient ( 2 new blister day ) signature inform consent Patient 2 sex Age 6 month 8 year . From age consider patient less need treatment take cyclines . Systematic Obtaining consent lit ( enlighten ) relative ( parent ) child , information objective constraint study . Agreement minor Patient member Social Security Patient allergic erythromycin Patient present intolerance fructose , syndrome malabsorption glucose galactose deficit sucraseisomaltase Renal and\or hepatic Insufficiency Patient take medicine indicate misadvised association erythromycin</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>